Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial.
Thomas GraillonMarc SansonChantal CampelloAhmed IdbaihMatthieu PeyreHadrien PeyrièreNoémie BassetDidier AutranCatherine RocheMichel KalamaridesPierre-Hugues RocheStéphane FuentesEmeline TabouretMaryline BarrieAnita CohenStéphane HonoréMohamed BoucekineKarine BaumstarckDominique Figarella-BrangerAnne BarlierHenry DufourOlivier Louis ChinotPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
The combination of everolimus and octreotide was associated with clinical and radiological activity in aggressive meningiomas and warrants further studies. Decrease in the tumor volume growth rate should be considered a complementary and sensitive endpoint to select potentially effective drugs for recurrent meningiomas.